Evidence map›Paper›PMID 35651922›Full record

ArticleComputational and mathematical methods in medicine2022

Value of 5-Hydroxymethylcytosine in HBV-Carrying High-Risk Hepatocellular Carcinoma Population: An Evaluation Based on Differential Analysis.

Jiao Yu, Guofeng Gao, Jing Wang, Jieqiong Zhao, Yu Zhang, Dong Jiang, Feihu Huang

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiao YuDepartment of Infection, The Third Affiliated Hospital of Naval Military Medical University, Shanghai 200000, China.
Guofeng GaoDepartment of Infection, The Third Affiliated Hospital of Naval Military Medical University, Shanghai 200000, China.
Jing WangDepartment of Disease Prevention and Control, The Third Affiliated Hospital of Naval Military Medical University, Shanghai 200000, China.
Jieqiong ZhaoDepartment of Outpatient Service, The Third Affiliated Hospital of Naval Military Medical University, Shanghai 200000, China.
Yu ZhangDepartment of Infection, The Third Affiliated Hospital of Naval Military Medical University, Shanghai 200000, China.
Dong JiangDepartment of Ultrasound Clinic, The Third Affiliated Hospital of Naval Military Medical University, Shanghai 200000, China.ORCID https://orcid.org/0000-0001-7099-1119
Feihu HuangDepartment of Disease Prevention and Control, The Third Affiliated Hospital of Naval Military Medical University, Shanghai 200000, China.ORCID https://orcid.org/0000-0001-7241-8578
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To clarify the application value of 5-hydroxymethylcytosine (5hmC) in evaluating the progression of chronic hepatitis B (CHB) to hepatocellular carcinoma (HCC) based on difference analysis. Methods: A total of 180 patients were enrolled. Among them, 84 patients with chronic hepatitis B virus (HBV) infection while no progression to hepatocellular carcinoma (HCC) were included in the control group (CG), and 96 patients with HCC developed from HBV infection were included in the research group (RG). Two-thirds of the samples were used in the training set and 1/3 samples in the validation set to detect the level of 5hmC in both groups based on the modified nano-hmC-Seal technique. The expression levels of 5hmC-related genes TET2 and TET3 were quantified by qPCR, and the correlation between TET3 and 5hmC was analyzed by Pearson's correlation coefficients. Receiver operating characteristic (ROC) curves were drawn to evaluate the application value of the TET3-based 5hmC prediction model in the early diagnosis of HCC. Results: (i) The expression of 5hmC in RG was lower than that in CG, no matter in the training set or the validation set. (ii) 5hmC was significantly enriched in the region between the transcription initiation site and the transcription end site but was depleted in the flanking region. (iii) 5hmC-related genes TET2 and TET3 were significantly downregulated in HCC patients, whether in the training set or the validation set. (iv) In both the training and validation sets, TET3 showed a positive association with 5hmC. (v) ROC analysis results showed that the 5hmC prediction model could be used to predict the progression of CHB to HCC (training set: AUC = 0.81, 0.729-0.893; validation set: AUC = 0.84, 0.739-0.936). Conclusions: TET3 expression based on 5hmC sequencing is a landmark molecule for evaluating the progression of HCC in CHB patients, which is worthy of further study and promotion.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicLiver Neoplasms5-MethylcytosineHepatitis B virusHumans5-hydroxymethylcytosine5-Methylcytosine

Identifiers

PMID35651922
PMCPMC9150989
OpenAlexW4281396803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.